Evaluation of a new dengue 3 controlled human infection model for use in the evaluation of candidate dengue vaccines.

K K Pierce,S S Whitehead, S A Diehl, G Naro, M C Carmolli,H He,C M Tibery,B P Sabundayo,B D Kirkpatrick,A P Durbin

medRxiv (Cold Spring Harbor Laboratory)（2023）

Cited 0|Views9

No score

Abstract

All four serotypes of dengue virus (DENV) cause the full spectrum of disease. Therefore, vaccines must protect against all serotypes. To evaluate candidate vaccines, a human challenge model of dengue serotype 3 (rDEN30Δ30) was developed. All challenge virus recipients safely met the primary endpoint of viremia and secondary endpoints of rash and seroconversion to DENV-3.

Translated text

Key words

new dengue,human infection model,vaccines

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined